Illinois Precision Medicine Consortium

伊利诺伊州精准医学联盟

• 批准号: 10628963
• 负责人: Habibul Ahsan
• 金额: $ 1071.53万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-06-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10628963
• 关键词: Illinois; Text; precision medicine

1.1 Overview Precision medicine seeks to capitalize on growing capabilities in the areas of genomics, clinical phenotyping, clinical informatics, electronic health record (EHR) availability and interoperability, and mobile health technologies to improve understanding of human health and disease. Improved understanding of the complex interplay of genetic and environmental exposures, beyond those previously available in long-term observational epidemiological research, holds the promise of better prediction, prevention, and treatment of a host of human diseases including coronary heart disease, stroke, numerous cancers, dementing illnesses, arthritis, and other major causes of disability and early death. Internationally, efforts to address the opportunities of precision medicine have led to the assembly of large cohorts in the UK (UK Biobank), the China Kadoorie Biobank, and in a selected sub-population in the US (the Million Veteran Project - MVP). In January 2015, President Obama announced a plan for the Precision Medicine Initiative (PMI) to address this significant scientific opportunity. This is a unified multi-PI application (Drs. Greenland, Ahsan, Daviglus and Winn) from the Illinois Precision Medicine Consortium (IPMC) representing 3 major Chicago-area academic institutions (Northwestern University, University of Chicago, and the University of Illinois at Chicago) and their healthcare provider organization (HPO) partners, in response to OT-PM-18-001, Limited Competition: All of Us Research Program Regional Medical Center Healthcare Provider Organizations (OT2). Our goal is to continue our partnership with the All of Us Research Program (AoURP), to recruit and enroll a diverse patient population, contributing to the overall total of one million or more individuals across all age groups from both sexes, including both healthy people and those with pre-existing diseases (without regard to specific disease type), and to follow them through innovative mobile health technologies, electronic health records (EHR), and health insurance claims data to enable linkage of genetic and environmental exposures with a broad array of health outcomes. This consortium brings together the extensive preexisting research resources across the 3 academic institutions, as well as the widespread, yet geographically distinct, service areas of their HPO partners representing numerous ethnically and socioeconomically diverse Chicago and Illinois communities. These longstanding relationships of trust are well established. The IPMC has so far reached and exceeded milestones for organization, participation in national planning, and successful recruitment and logistics. For the OT award period, we will continue to utilize a highly participatory and empowered model of diverse participant engagement and enrollment. The data collected from the geographically and ethnically diverse IPMC population, representing the largest and most diverse urban metropolitan area in the Midwestern United States, will add significant value to the overall AoURP goal of enrolling, retaining, and interacting with 1 million US residents. We have assembled a multidisciplinary team of academic researchers, community partners, and health system leaders in the past year. This application builds upon the collective experience and demonstrated success of the 3 partnering institutions in assembly and retention of large epidemiological cohorts, questionnaire data collection, community-based participatory research, minority health research, EHR linkage for genetic research, and their established and ongoing cross- institution collaborations. For this 5-year project period, IPMC plans to enroll 20,000 full participants each year during Years 1 to 3, 18,000 full participants in Year 4, and 15,000 full participants in Year 5. As such, we will consent, conduct physical measurements, collect biospecimens, and transmit curated data to the AoURP Data and Research Center (DRC; Vanderbilt University) and processed biosamples to the AoURP Biobank (Mayo Clinic), on at least 93,000 people from diverse ethnic, social, and economic backgrounds. Further, we aim to broaden our enrollment from patients in IPMC HPOs (and their affiliates), to include direct volunteers (DV), once this capability becomes technically feasible. To reach enrollment milestones, we will engage HPO staff, patients, and the general community to generate support for and participation in the HPO cohort. We will also engage DV corporate partners, such as Walgreens which is headquartered in Deerfield, IL, to collaborate on implementation of HPO/DV Hybrid strategies. We will continue detailed tracking of success rates, including percentage participation and diversity of participation, and discern the most effective recruitment strategies for each participating HPO. We will also continuously adapt, refine and introduce new approaches to maintain recruitment targets. When available, we will employ mobile technologies as developed by the Technology Coordinating Center, and continuously engage participants to remain connected to the AoURP. In aggregate, the academic institutions, HPOs, and community partners represented in this application provide unparalleled expertise and opportunity to reach a geographically and demographically broad and diverse population that is representative of the US as a whole. The population of the greater Chicago and Illinois area brings a unique opportunity to study common and unique environmental, behavioral and genetic underpinnings of health and disease that can inform the precision medicine of tomorrow.

1.1 概述 精准医学寻求利用基因组学、临床表型分析、临床信息学、电子健康记录 (EHR) 可用性和互操作性以及移动医疗技术等领域不断增长的能力，以增进对人类健康和疾病的了解。进一步了解遗传和环境暴露之间复杂的相互作用，超越了以前长期观察流行病学研究的范围，有望更好地预测、预防和治疗许多人类疾病，包括冠心病、中风、多种癌症、痴呆症、关节炎以及其他导致残疾和过早死亡的主要原因。在国际上，为抓住精准医疗机遇而做出的努力已导致在英国（英国生物银行）、中国嘉道理生物银行以及美国选定的亚人群（百万退伍军人项目 - MVP）中组建了大型队列。 2015 年 1 月，奥巴马总统宣布了一项精准医学计划 (PMI) 计划，以抓住这一重大科学机遇。 这是来自伊利诺伊州精密医学联盟 (IPMC) 的统一多 PI 应用程序（Greenland、Ahsan、Daviglus 和 Winn 博士），代表芝加哥地区 3 个主要学术机构（西北大学、芝加哥大学和伊利诺伊大学芝加哥分校）及其医疗保健提供者组织 (HPO) 合作伙伴，响应 OT-PM-18-001，有限竞争：我们所有人研究计划 区域医疗中心医疗保健提供者组织 (OT2)。我们的目标是继续与“我们所有人研究计划”(AoURP) 合作，招募和登记多样化的患者群体，为所有性别的所有年龄组的总共 100 万或更多的患者做出贡献，包括健康人和患有既往疾病的人（不考虑特定疾病类型），并通过创新的移动医疗技术、电子健康记录 (EHR) 和健康保险索赔数据来跟踪他们，以实现遗传基因的链接。 和环境暴露会产生广泛的健康结果。该联盟汇集了 3 个学术机构广泛的现有研究资源，以及代表芝加哥和伊利诺伊州众多种族和社会经济多元化社区的 HPO 合作伙伴广泛但地理上不同的服务领域。这些长期的信任关系已经建立得很好。 迄今为止，IPMC 在组织、参与国家规划以及成功招募和后勤方面已达到并超越了里程碑。在 OT 奖励期间，我们将继续采用高度参与和授权的多元化参与者参与和注册模式。从地理和种族多样化的 IPMC 人口中收集的数据（代表美国中西部最大、最多样化的城市大都市区）将为 AoURP 的总体目标（即招募、留住 100 万美国居民并与之互动）增加重要价值。去年，我们组建了一支由学术研究人员、社区合作伙伴和卫生系统领导者组成的多学科团队。该应用程序建立在 3 个合作机构在收集和保留大型流行病学队列、问卷数据收集、基于社区的参与性研究、少数民族健康研究、遗传研究的 EHR 链接以及已建立和正在进行的跨机构合作方面的集体经验和展示的成功之上。 在这个为期 5 年的项目期间，IPMC 计划在第 1 至第 3 年每年招收 20,000 名正式参与者，在第 4 年招收 18,000 名正式参与者，在第 5 年招收 15,000 名正式参与者。因此，我们将同意、进行物理测量、收集生物样本，并将整理的数据传输到 AoURP 数据和研究中心（DRC；范德比尔特大学），并将处理后的生物样本传输到 AoURP生物银行（梅奥诊所），至少 93,000 名来自不同种族、社会和经济背景的人。此外，一旦这种能力在技术上可行，我们的目标是扩大 IPMC HPO（及其附属机构）的患者招募范围，将直接志愿者 (DV) 纳入其中。为了达到入组里程碑，我们将让 HPO 工作人员、患者和广大社区参与进来，为 HPO 队列提供支持和参与。我们还将与总部位于伊利诺伊州迪尔菲尔德的沃尔格林等 DV 企业合作伙伴合作，合作实施 HPO/DV 混合战略。我们将继续详细跟踪成功率，包括参与百分比和参与多样性，并为每个参与的 HPO 找出最有效的招聘策略。我们还将不断调整、完善和引入新方法来维持招聘目标。如果可行，我们将采用技术协调中心开发的移动技术，并不断吸引参与者与 AoURP 保持联系。总的来说，本申请中代表的学术机构、HPO 和社区合作伙伴提供了无与伦比的专业知识和机会，以接触代表整个美国的地理和人口广泛且多样化的人口。大芝加哥和伊利诺伊州地区的人口带来了独特的机会来研究健康和健康的常见和独特的环境、行为和遗传基础。 可以为明天的精准医学提供信息的疾病。